A. David Mazzone Research Awards Program

The A. David Mazzone Research Awards Program funds a series of collaborative and innovative cancer research, career development, community outreach, and training projects to address a range of needs in prostate cancer and Lupron-treatable diseases. This $12 million funding program is a grant from the U.S. District Court for the District of Massachusetts from a pool of unclaimed funds from the 2004 class action suit settlement by TAP Pharmaceuticals. The class action suit was related to marketing and sales practices for the prostate cancer drug Lupron. The Program is administered jointly through DF/HCC and the Prostate Cancer Foundation, and was named in memory of the Honorable Judge A. David Mazzone (June 3, 1928 – October 25, 2004).

View the complete list of Mazzone award recipients by year below.

2014

Cancer Disparities

Do Baseline Prostate Specific Antigen (PSA) Levels Predict Advanced Prostate Cancer in African-American Men?
Principal Investigator: Mark Preston, MD, MPH (BWH)
Collaborator: Lorelei Mucci, ScD (HSPH)

Whole genome sequencing based identification of clinically relevant genomic aberrations specific to prostate cancer cases in African Americans
Principal Investigator: Zoltan Szallasi, MD (BCH)
Co-Principal Investigator: Matthew Freedman, MD (DFCI)
Collaborator: Mark Pomerantz, MD (DFCI)

2013

Career Development 

Impact on Prognosis of Inter- and Intratumor Heterogeneity In Prostate Cancer
PI: Jennifer Sinnott, PhD (HSPH)
Mentors: Lorelei Mucci, ScD (HSPH); Giovanni Parmigiani, PhD (DFCI)
Collaborators: Massimo Loda, MD (DFCI); Kathryn Penney, ScD (BWH)

Community Outreach

Shared Medical Appointments: An Innovative Approach to Prostate Cancer Survivorship Care
PI: Larissa Nekhlyudov, MD, MPH (Harvard Vanguard Medical Associates)
Collaborators: Ann Partridge, MD, MPH (DFCI); Wilmer Roberts, MD, PhD (Harvard Vanguard Medical Associates); Michael Pistiner, MD, MMSc (Harvard Vanguard Medical Associates); Aymen Elfiky, MD, MPH (DFCI); Christopher Recklitis, PhD, MPH (DFCI); Sarah Reed, MPH, MSW (DFCI)

Disparities Research

Chronic stress and racial disparities in prostate cancer
PI: Lisa Signorello, ScD (HSPH)
Collaborators: Jennifer Rider, ScD (HSPH); Sebastien Haneuse, PhD (HSPH); Unnur Valdimarsdottir, PhD (University of Iceland)

High Impact Projects

Co-targeting AR and ERG to treat advanced prostate cancer
PI: Karen Knudsen, PhD (Thomas Jefferson University)
Co-PIs: Felix Feng, MD (University of Michigan); Myles Brown, MD (DFCI)

Genome-wide analysis of response to androgen deprivation therapy
PI: Mark Pomerantz, MD (DFCI)
Collaborators: Matthew Freedman, MD (DFCI); Christopher Sweeney, MBBS (DFCI); Manish Kohli, MBBS (Mayo Clinic); Svitlana Tyekucheva, PhD(DFCI)

Targeting Androgen Receptor Pathway-Independent Prostate Cancer (APIPC)
PI: Peter Nelson, MD (Fred Hutchinson Cancer Research Center)
Co-PI: Marc Vidal, PhD (DFCI)
Collaborator: Muneesh Tewari, MD, PhD (Fred Hutchinson Cancer Research Center)

High Impact Clinical Trials

Clinical Trials Assessing Mechanisms Mediating Sensitivity and Resistance to Enzalutamide
PI: Mary-Ellen Taplin, MD (DFCI)
Co-PIs: Bruce Montgomery, MD (University of Washington); Elahe Mostaghel, MD, PhD (Fred Hutchinson Cancer Research Center); Xin Yuan, MD, DSc (BIDMC)
Collaborators: Steven Balk, MD, PhD (BIDMC); Glenn Bubley, MD (BIDMC); Mark Pomerantz, MD (DFCI); Colm Morrissey, PhD (University of Washington)

Project Development

Developing Novel Targeted Therapies for Advanced Prostate Cancer
PI: Karen Cichowski, PhD (BWH)

Targeting the Co-Activator Site on the Androgen Receptor
PI: Gregory Verdine, PhD (Harvard University, Chemistry Department)
Collaborator: Levi Garraway, MD (DFCI)

Project Funded through the Prostate Cancer Foundation Mazzone Challenge Award

Synergistic Immune and lipid Metabolism Targeting for Metastatic Prostate Cancer Therapy
PI: Jennifer Wu, PhD, (Medical University of South Carolina)
Co-PIs: James S. Norris, PhD (Medical University of South Carolina); Michael Lilly, MD (Medical University of South Carolina); Xiang Liu, MD, PhD (Medical University of South Carolina); Ali Goshayan, MD (Medical University of South Carolina)
Collaborators: Richard Drake, PhD (Medical University of South Carolina); Ann-Marie Broome, PhD (Medical University of South Carolina); Elizabeth Garrett-Mayer, PhD (Medical University of South Carolina)

2012

High Impact Mazzone Awards Recipients

Molecular Characterization Of Gleason 3 Tumors That Progress To Gleason 4
PI: Steven Balk, MD, PhD (BIDMC)
Collaborator: Wei Li, PhD (Baylor College of Medicine)

Defining the spectrum of resistance to androgen ablation therapy in prostate cancer
PI: Levi Garraway, MD, PhD (DFCI)
Collaborators: William Hahn, MD, PhD (DFCI); Mark Rubin, MD (Weill Cornell Medical College)

Project Development Mazzone Awards Recipients

Castration-Resistant Luminal Cells in the Prostate
PI: Zhe Li, PhD (BWH)
Collaborator: Stuart Orkin, MD (BCH)

Developing a Blood-based Metabolomic Signature of Gleason Score
PI: Massimo Loda, MD (DFCI)
Collaborators: Kathryn Penney, ScD (BWH); Svitlana Tyekucheva, PhD (HSPH)

Nanoplatforms for Localized Chemo Radiation Therapy for Prostate Cancer
PI: Robert Cormack, PhD (DFCI)
Collaborators: Anthony D’Amico, MD, PhD (DFCI); Alec Kimmelman, MD, PhD (DFCI); Mike Makrigiorgos, PhD (DFCI); Srinivas Sridhar, PhD (Northeastern University)

Disparities Research Mazzone Awards Recipients

Estimating The Prostate Cancer Burden Attributed To Lifestyle And Genetic Factors Among African-American And White Men
PI: Lorelei Mucci, ScD (HSPH)
Collaborators: Edward Giovannucci, MD, ScD (HSPH); Massimo Loda, MD (DFCI); Lisa Signorello, ScD (Vanderbilt University)

Factors Influencing Willingness To Participate In Biobanking Among Black Men With And At-Risk For Prostate Cancer
PI: Karen Emmons, PhD (DFCI)
Collaborators: Laura Hayman, PhD (University of Massachusetts Boston); J Jacques Carter, MD (BIDMC); Aymen Elfiky, MD (DFCI); Christopher Lathan, MD (DFCI)

Career Development Mazzone Awards Recipients

Within-Person Molecular Differences in Primary Versus Metastatic Prostate Cancer
PI: Julie Kasperzyk, ScD (BWH)
Collaborators: Steven Balk, MD, PhD (BIDMC); Giovanni Parmigiani, PhD (HSPH); Meir Stampfer, MD, DrPH (BWH)

PI: Jennifer Rider, ScD (HSPH)
Collaborators: Lorelei Mucci, ScD (HSPH); Giovanni Parmigiani, PhD (DFCI); Christopher Sweeney, MBBS (DFCI); Michelangelo Fiorentino, MD, PhD (HSPH); Ove Andren, MD, PhD (University of Orebro)

Lupron-Treatable Diseases and Conditions Mazzone Awards Recipients
Targeting estrogen-dependent mechanisms in lymphangioleiomyomatosis (LAM)
PI: Elizabeth Henske, MD (BWH)
Collaborator: Jane Yu, PhD(BWH)

Pre-clinical in vivo studies investigating the efficacy of mTOR inhibitors for uterine fibroids
PI: Jose Teixeira, PhD (MGH)
Collaborator: Bradley Quade, MD, PhD (BWH)

Prostate Cancer Foundation Mazzone Awards Recipients
Promoter-Driven Molecular Radiotherapy for Prostate Cancer
PI: Martin Pomper, MD, PhD (Johns Hopkins Medicine)
Collaborators: George Sgouros, PhD (Johns Hopkins Medicine); Paul Fisher, PhD (Virginia Commonwealth University).

Targeting the p160 Steroid Receptor Coactivators (SRCs) as a Novel Approach for the Treatment of Castration-Resistant Prostate Cancer
PI: Bert O’Malley, MD (Baylor College of Medicine)
Collaborators: Nancy Weigel, PhD (Baylor College of Medicine); Ming-Jer Tsai, PhD (Baylor College of Medicine); Francesco DeMayo, PhD (Baylor College of Medicine); Michael Ittman, MD, PhD (Baylor College of Medicine); Nicholas Mitsiades, MD, PhD (Baylor College of Medicine); Sean McGuire, MD, PhD (Baylor College of Medicine)

Community Outreach Mazzone Awards Recipients

Engaging African American Faith Communities in Prostate Cancer Education
PI: Jennifer Allen, DSc, MPH (DFCI)
Collaborator: Donna Berry, PhD, RN (DFCI)

2011

High Impact Mazzone Awards Recipients

Functional Annotation of Prostate Cancer Risk Loci Discovered through Genome Wide Association Studies
PI: Matthew Freedman, MD (DFCI)
Collaborator: Gerhard Coetzee, PhD (USC/Norris Cancer Center - Keck School of Medicine)

Project Development Mazzone Awards Recipients

Epigenetic Reprogramming of AR Function in CRPC
PI: Myles Brown, MD (DFCI)

Pharmacological validation of Etk/BMX as a target for the treatment of prostate cancer
PI: Nathanael Gray, PhD (DFCI)
Collaborator: Steven Balk, MD, PhD (BIDMC)

Cancer Stem Cells Targeting in Castration Resistant Prostate Cancer
PI: Pier Paolo Pandolfi, MD, PhD (BIDMC)

DNase-seq for Cost-effective Identification of Functional Mutations in Prostate Cancers
PI: Xiaole Shirley Liu, PhD (DFCI)
Collaborators: Myles Brown, MD (DFCI); Levi Garraway, MD, PhD (DFCI); Soumya Raychaudhuri, MD, PhD (HMS)

Disparities Research Mazzone Awards Recipients

Enhancing Usability of the Personal Patient Profile-Prostate (P3P) for Black and Hispanic Men
PI: Donna Berry, PhD, RN (DFCI)
Collaborators: Julia Hayes, MD (DFCI); Martin Sanda, MD (BIDMC); Seth Wolpin, PhD, MPH, RN (University of Washington)

Understanding Racial Differences in Prostate Cancer Mortality
PI: Nancy Keating, MD, MPH (HMS)
Collaborators: Glen Taksler, PhD (New York University); David Cutler PhD (Harvard University School of Economics)

Career Development Mazzone Awards Recipients

Probing androgen receptor signaling in circulating tumor cells in prostate cancer
PI: David Miyamoto, MD, PhD (MGH)
Collaborator: Daniel Haber, MD, PhD (MGH)

Prostate cancer genetic variants, molecular alterations and mRNA expression
PI: Kathryn Penney, ScD (BWH)
Collaborator: Massimo Loda, MD (BWH)

Phosphorus and calcium intake, tumor microenvironment and prostate cancer progression
PI: Kathryn Wilson, ScD (HSPH)
Collaborators: Lorelei Mucci, MPH, ScD (BWH); Edward Giovannucci, MD, ScD (HSPH); Michelangelo Fiorentino, MD, PhD (HSPH)

Lupron-Treatable Diseases and Conditions Mazzone Awards Recipients
Cancer and Endometriosis
PI: Stacey Missmer, ScD (BWH)
Collaborators: Rulla Tamimi, ScD (BWH); Jiali Han, PhD (BWH)

Prostate Cancer Foundation Mazzone Awards Recipients

Imaging Biomarkers of Treatment Response Using NaF PET/CT Imaging: a Prostate Cancer Clinical Trials Consortium (PCCTC) Effort
PI: Glenn Liu, MD (UW Carbone Cancer Center)
Collaborators: Michael Morris, MD (Memorial Sloan-Kettering Cancer Center); William Dahut, MD (National Cancer Institute); Steven Larson, MD (Memorial Sloan-Kettering Cancer Center); Peter Choyke, MD (National Cancer Institute); Robert Jeraj, PhD, (UW Carbone Cancer Center)

Induction of Synthetic Lethality with Epigenetic therapy (ISLET) for Systemic Treatment of Prostate Cancer
PI: William G. Nelson, MD, PhD (Johns Hopkins Medicine)
Collaborators: Srinivasan Yegnasubramanian, MD, PhD (Johns Hopkins Medicine); Jun O. Liu, PhD, (Johns Hopkins Medicine); Stephen B. Baylin, MD (Johns Hopkins Medicine); Michael A. Carducci, MD (Johns Hopkins Medicine); Martin J. Aryee, PhD (Johns Hopkins Medicine)